Olema Pharma CFO granted 650K stock options

Olema Pharmaceuticals’ chief financial officer received a sizable stock option grant with long-term, service-based vesting.

Rhea-AI Filing Summary

Olema Pharmaceuticals, Inc. (OLMA) reported that its Chief Financial Officer, Jason O'Byrne, received a grant of stock options covering 650,000 shares of common stock on September 1, 2026. The options have an exercise price of $10.56 per share and expire on August 31, 2036.

According to the award terms, 25% of the shares subject to the option vest on August 11, 2027, and the remaining shares vest in equal monthly installments over the following 36 months, subject to his continuous service. Following this grant, he holds stock options for 650,000 shares directly.

Insider Trade Summary

Grant/Award: 650,000 shares

Grant/Award 1 txn

Insider O'Byrne Jason

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	650,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 650,000 contracts (Direct)

Footnotes (1)

1. F1. 25% of the shares subject to the option vest on August 11, 2027 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

Key Figures

Stock options granted: 650,000 shares Exercise price: $10.56 per share Underlying common shares: 650,000 shares +3 more

6 metrics

Stock options granted 650,000 shares Grant of stock options to CFO on September 1, 2026

Exercise price $10.56 per share Exercise price for the 650,000 stock options granted

Underlying common shares 650,000 shares Common stock underlying the stock option award

Post-transaction option holdings 650,000 shares Total stock options held directly by CFO after the grant

Vesting cliff portion 25% of shares First vesting on August 11, 2027, then monthly vesting thereafter

Option expiration date August 31, 2036 Expiration of the granted stock options

Key Terms

Stock Option (Right to Buy), vesting, exercise price, expiration date

4 terms

Stock Option (Right to Buy) financial

"The reported security is a Stock Option (Right to Buy) on common stock"

vesting financial

"25% of the shares subject to the option vest on August 11, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"The options have an exercise price of $10.56 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"The options expire on August 31, 2036"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

What did OLMA’s CFO Jason O'Byrne report in this Form 4?

He reported a grant of stock options for 650,000 shares of Olema Pharmaceuticals common stock on September 1, 2026, with an exercise price of $10.56 per share and expiration on August 31, 2036.

What is the vesting schedule for the OLMA stock options granted to the CFO?

25% of the option shares vest on August 11, 2027, and 1/48 of the total shares vest monthly thereafter, conditioned on Jason O'Byrne’s continuous service through each vesting date.

How many OLMA option shares does the CFO hold after this reported transaction?

After the reported grant, Jason O'Byrne holds stock options covering 650,000 shares of Olema Pharmaceuticals common stock directly, as stated in the filing.

Was the OLMA CFO’s Form 4 transaction a purchase or a grant?

The transaction was a grant/award acquisition of stock options, not an open-market purchase or sale. It is reported as an acquisition of derivative securities (stock options).

Is the OLMA CFO’s option grant tied to any Rule 10b5-1 trading plan?

No. The Form 4 indicates that the Rule 10b5-1 checkbox is not marked, and there is no footnote stating that the grant was made under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:32 PM Accepted by SEC EDGAR 09/02/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Byrne Jason

(Last) (First) (Middle)

C/O OLEMA PHARMACEUTICALS, INC.

780 BRANNAN ST

(Street)

SAN FRANCISCO CALIFORNIA 94103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Olema Pharmaceuticals, Inc. [ OLMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.56	09/01/2026		A		650,000		(1)	08/31/2036	Common Stock	650,000	$0	650,000	D

Explanation of Responses:

1. 25% of the shares subject to the option vest on August 11, 2027 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

	/s/ Shawnte Mitchell, Attorney-in-Fact	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)